HomeAboutEfficacyEfficacyEfficacyTrial DesignSafetySafetyImportant Safety InformationSafety & TolerabilityDosingDosingDosing InformationDose AdjustmentsDrug InteractionsMedical InformationVisit the Pfizer Medical Information Africa Website for Healthcare ProfessionalsSubmit a medical question to Pfizer
Identify potential drug interactions before treatment begins1Nirmatrelvir/Ritonavir Pfizer should not be coadministered with other CYP3A4 substrates unless the benefits outweighs the risks because the coadministration may lead to potentially significant interaction.1
Most DDIs can be managed safely by temporarily withdrawing the problematic comedication2
In some circumstances, DDIs cannot be prevented by this approach, either because of persisting effects (ie carbamazepine or rifampicin) or a very long half-life of the comedication (ie amiodarone)2
These DDIs may result in inadequate exposure to PF-07321332 or toxic drug levels2
An alternative COVID-19 treatment would be considered in such situations2
Nirmatrelvir/Ritonavir Pfizer may cause drug interactions1
Before prescribing Nirmatrelvir/Ritonavir Pfizer, identify any medicinal products your patient may be taking, as some may be contraindicated for concomitant use or may create potentially significant drug interactions requiring dose adjustments or additional monitoring
Ritonavir is a widely used treatment with a known profile3,4
Ritonavir is used in combination with other antivirals to similarly inhibit drug metabolism1,2
EXPLORE MOREEfficacy & trial design
Discover the efficacy data and trial design of EPIC-HR.
Efficacy Loading Trial design LoadingReferences: 1. Nirmatrelvir/ ritonavir Pfizer Summary of Product Characteristics. 2. Marzolini C, Kuritzkes DR, Marra F, et al. Prescribing nirmatrelvir-ritonavir: how to recognize and manage drug-drug interactions. Ann Intern Med. 2022;175(5):744-746. 3. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593. 4. NORVIR Summary of Product Characteristics.Dosing
Contact: KENYA OFFICE: Pfizer Laboratories (Pty) Ltd Vienna Court, First Floor West Wing, State House Crescent, State House Road, Nairobi Kenya, PO Box 18244-00500.
Tel: +254(0)5134110.
This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.
You are now leaving Accord Portal to access Pfizer Medical Information Portal You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.